Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

NVSNovartis PharmaceuticalsRunning, no new patients

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia - Chronic Phase

10Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • Main results were due Aug 2025, none posted yet

    Counts until it's fixed

    +10
Worry score10

Score over time

Stage
Phase 2
Patients
34 (final count)
Started
Nov 11, 2022
Main results expected
Aug 13, 2025
Fully finished
Oct 17, 2027
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Percentage of participants who achieve Major Molecular Response (MMR) in the 2L setting

    Measured over: Baseline up to 12 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • results_overdue: base 10, now 10, since 2025-08-13, no fading

Raw record changes

  • none yet

Trial ID NCT05384587 · record last updated 2025-10-14 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT05384587) ↗